All In Biotech

Drug Trial Radar · NCT06723652

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

55

Actual

Start

Feb 13, 2025

Primary completion

Aug 25, 2025

Study completion Nov 18, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).

Conditions

  • Homozygous Familial Hypercholesterolemia

Interventions

  • SHR-1918Drug

    six administration

  • SHR-1918 placeboDrug

    SHR-1918 placebo three administration+SHR-1918 three administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in calculated LDL-C from baseline to week 12Time frame: week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Xiangya Hospital of Central South University Hospital

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.